Press Releases

HiFiBiO Therapeutics, a multinational biotherapeutics company with unique expertise in immune modulation and single cell science, today announced a partnership with Russian pharmaceutical company, Pharmsynthez PJSC (MOEX: LIFE), and Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry RAS (IBCh). The partnership aims to advance HFB30132A, a SARS-CoV-2 neutralizing antibody for the treatment of COVID-19, through clinical development and commercial sale in Russia, pending approval from t

Pfizer Inc. and BioNTech SE announced they will submit a request to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of their mRNA vaccine candidate, BNT162b2 against SARS-CoV-2, which will potentially enable use of the vaccine in high-risk populations in the U.S. by the middle to end of December 2020. The submission is based on a vaccine efficacy rate of 95% (p<0.0001) demonstrated in the companies’ Phase 3 clinical study in participants wi

Health industry digitalization is one of the highest priorities in the healthcare sector these times. In perspective, it improves current living standards with quicker and easier access to help. The Healthcare Automation and Digitalization Congress business program will cover digital trends in the healthcare industry. The Congress will take place in Zurich, Switzerland on the 22nd - 23rd of March, 2021. Growth of pharmaceutical costs, poorly inte

The U.S. Food and Drug Administration approved Zokinvy (lonafarnib) capsules to reduce the risk of death due to Hutchinson-Gilford progeria syndrome and for the treatment of certain processing-deficient progeroid laminopathies in patients one year of age and older. Zokinvy is not approved for use in patients with other progeroid syndromes or laminopathies. "Hutchinson-Gilford progeria syndrome and progeroid laminopathies are rare genetic diseases that cause premature aging and

Tellic, a technology startup based in New York, NY has created software and a data curation pipeline that accelerate modern drug discovery. tellic solutions make actionable the growing amount of siloed biomedical datasets, and enable faster and earlier decision-making driven by high-quality integrated data. Today, R&D IT teams are tasked with the enormous challenge of organizing and surfacing the right data to science customers. To support this work, tellic partners with teams a

Zymeworks Inc., a clinical-stage biopharmaceutical company that develops multifunctional biotherapeutics, announced that the European Commission (EC) has granted the orphan drug designation for zanidatamab, its experimental bispecific antibody targeting the HER2 receptor, for the treatment of patients with gastric cancer. "The recognition by the European Commission and the European Medicines Agency of the potential benefit provided by zanidatamab in terms of the treatment of ga

F4 Pharma, a clinical-stage biopharmaceutical company developing FX06, an anti-inflammatory therapeutic that has shown to improve vascular integrity, announces today the inclusion of the first patient with severe COVID-19 in a study named “FX-COVID”. The randomized, double-blind, placebo-controlled FX-COVID trial which is conducted by AP-HP  (Assistance Publique –Hopitaux de Paris) in France, is set up to confirm the efficacy and safety of FX06 in hospitalized patients

BioVersys has reached a major milestone by entering clinical development with the start of Phase 1 testing of BV100 in healthy volunteers. BioVersys AG, a privately owned, multi-asset Swiss pharmaceutical company focused on developing small molecules for multidrug-resistant bacterial infections with applications in Anti-Microbial Resistance (AMR) and targeted microbiome modulation, today announced that the first healthy volunteers have received BV100 in a Phase 1 clinical trial designed to ev

SIRIO – a leading nutraceutical contract development and manufacturing organisation (CDMO) – has completed a new ‘smart factory’ at its Ma’anshan site, with Internet of Things (IoT) enabled automated processes and monitoring, intelligent distribution robotics and Artificial intelligence (AI). Sirio is a first adopter of smart factory tech (industry 4.0) among nutraceuticals manufacturers, bringing a level of reporting, manufacturing control, production

ProBioGen AG announced the closing of a master service agreement with Asahi Kasei Pharma. As an expert CDMO in high-titer cell line development till large scale GMP manufacturing, ProBioGen will use its proprietary technologies, like the CHO.RiGHT® cell line development platform and DirectedLuck™ transposase technology, to enable Asahi Kasei Pharma to advance their biologics pipeline. “We are enchanted to work with Asahi Kasei Pharma on one of their key projects and